All In MedTech

Device Trial Radar · NCT01533038

BPH-6: Comparison of the UroLift System to TURP for Benign Prostatic Hyperplasia

BPH-6: A UroLift® System Post Market Multi-Center Randomized Study

Last checked: Nov 19, 2026Latest source record: Dec 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Feb 2012

Primary completion

Oct 2015

Study completion Jan 2016

Sponsor

Lead sponsor
NeoTract, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Feb 15, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the UroLift System Treatment to Transurethral Resection of the Prostate (TURP) in improving a patient's overall quality of life, while evaluating healthcare expenditures associated with each therapy.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • UroLift SystemDevice

    The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.

  • Transurethral Resection of the ProstateProcedure

    Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder Analysis: A Subject is a Responder at the 12 Month Follow-up Time Point if All 6 Thresholds of the BPH-6 Endpoint Are MetTime frame: Month 12

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Herlev Hospital

    Herlev, Denmark

  • PAN Klinik

    Cologne, Germany

  • University Hospital Freiburg

    Freiburg im Breisgau, Germany

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.